Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
There’s been a lot of grim news lately about HIV and AIDS: Rising infections among high-risk U.S. communities, continued risk behaviors, and plague-level infection rates across sub-Saharan Africa. In ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...
It is beyond the scope of this article to describe all possible drug-drug interactions in persons taking HIV antiretroviral medications, but this section will identify the most frequent interactions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback